They found that high expression of the m6A methylase METTL3 in HCC patients leads to high levels of m6A in SOCS2 mRNA, resulting in the rapid degradation of SOCS2 and HCC occurrence (79), while METTL14 had no significant effect on HCC, and down-regulation of METTL14 expression was related with a poor prognosis in HCC patients without recurrence (80). The gene discussed is METTL3; the disease is hepatocellular carcinoma.